Peru’s Ex-President Martín Vizcarra Sentenced to 14 Years in Prison for Corruption 
Trump and Merck KGaA Partner to Slash IVF Drug Costs and Expand Fertility Coverage 
China Urged to Prioritize Economy Over Territorial Ambitions, Says Taiwan’s President Lai 
Tabletop particle accelerator could transform medicine and materials science 
Dollar Slides to Five-Week Low as Asian Stocks Struggle and Markets Bet on Fed Rate Cut 
Lost in space: MethaneSat failed just as NZ was to take over mission control – here’s what we need to know now 
Australia Moves Forward With Teen Social Media Ban as Platforms Begin Lockouts 
Japan’s Nikkei Drops as Markets Await Key U.S. Inflation Data 
Netflix’s Bid for Warner Bros Discovery Aims to Cut Streaming Costs and Reshape the Industry 
SpaceX Starship Test Flight Reaches New Heights but Ends in Setback 
Meta Accused of Halting Internal Research on Mental Health Risks of Facebook and Instagram 
Pfizer Secures $10 Billion Deal for Obesity Drug Developer Metsera, Outbids Novo Nordisk 
U.S. Justice Department Orders Intensified Probe Into Antifa and Domestic Extremist Groups 
Asian Currencies Edge Higher as Markets Look to Fed Rate Cut; Rupee Steadies Near Record Lows 
Singapore Court Allows $2.7 Billion 1MDB Lawsuit Against Standard Chartered to Proceed 
Cogent Biosciences Soars 120% on Breakthrough Phase 3 Results for Bezuclastinib in GIST Treatment 
The Seoul Central District Court had ruled that Medytox's patents for botulinum toxin (botox) strains and manufacturing process were stolen by Daewoong Pharmaceutical in developing Nabota.
Thus, the court prohibited Daewoong from manufacturing and selling its botox products, ordering that those that have already been produced should be discarded.
It also ordered Daewoong to pay 40 billion won in damages to Medytox, the first Korean company to succeed in mass-producing botox strains.
Medytox sued Daewoong in 2017, accusing it of stealing its botox strain and manufacturing process.
Daewoong claimed that it found its botox strain in a barn in Gyeonggi Province.
Medytox vowed to continue to protect its patent, while Daewoong said it would appeal the ruling.
The US International Trade Commission (USITC) had earlier ruled in favor of Medytox in December 2020 and ordered a 21-month import ban on Daewoong's products into the US. Daewoong also agreed to pay royalties to Medytox to settle the dispute shortly after the USITC decision.
